Fig. 1. p53 deficiency is associated with MET inhibitor resistance in MPNSTs.

A Percent viability of NF1-MET and NF1-P53 cells after 72 h of capmatinib (100 nM), trametinib (40 nM) or combination (capmatinib 100 nM, trametinib 40 nM) treatment. B Change in phospho-site activation of MET effectors in NF1-P53 cells relative to NF1-MET cells upon capmatinib (100 nM), trametinib (100 nM), or combination (capmatinib 100 nM, trametinib 100 nM) treatment for 2 and 48 h. See also Supplementary Fig. 2. C IC₅₀ of p53 stabilizing drugs and MET inhibitors against a panel of human MPNST cell lines. D Spearman’s correlations (color) and significance (size) between the IC₅₀ of the drugs in (C). The rho value of correlations with a p-value < 0.5 are indicated in their respective bubble. The black box indicates the correlations between p53 stabilizing drugs and MET inhibitors. ***p < 0.001.